Although treatments for Tuberculosis have existed for over 75 years, it remains the world’s leading infectious disease killer. A major barrier to control has been diagnostic limitations. On one hand, conventional tests often miss up to half of all cases. On the other, accurate molecular tests require expensive laboratory infrastructure, which remains inaccessible in many high-burden regions.
MiniDock MTB: A Game-Changing Innovation
However, a new portable device, MiniDock MTB, could transform this landscape. In a study published in the The New England Journal of Medicine, researchers from University of California San Francisco and University of California Irvine demonstrated that the device delivers results in under 30 minutes. Importantly, it matches the accuracy of standard laboratory tests while operating at the point of care.
Expanding Access Through Simpler Testing
Unlike traditional methods that rely on sputum samples, MiniDock MTB can detect TB using alternative samples such as tongue swabs. This is particularly beneficial for children and individuals with HIV, who often struggle to produce sputum. Consequently, healthcare providers can now perform reliable molecular testing even in resource-limited settings.
Advanced Technology in a Portable Format
As reported by medicalxpress, the device uses molecular technology similar to hospital-based COVID-19 diagnostics to identify DNA from Mycobacterium tuberculosis. Additionally, it runs on battery power and requires minimal training, allowing frontline healthcare workers to use it effectively after simply reading the instructions.
Global Impact and WHO Endorsement
Notably, the findings have prompted the World Health Organization to issue its first recommendation for this type of test. This endorsement highlights the device’s potential to revolutionise TB diagnosis worldwide.
Towards Same-Day Diagnosis and Treatment
Ultimately, MiniDock MTB could enable same-day diagnosis and treatment, eliminating long waiting periods. As evidence continues to grow, experts expect wider adoption, paving the way for faster, more accessible TB care globally.